Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21388382 | 0.82 | MAN1B1 (0.36) | CA2LMNATHRBCYP2C9GSR | |
| SCHEMBL338223 | 0.82 | MAN1B1 (0.36) | CA2LMNATHRBCYP2C9GSR | |
| SCHEMBL9268731 | 0.82 | MAN1B1 (0.36) | CA2LMNATHRBCYP2C9GSR | |
| SCHEMBL18710271 | 0.82 | MAN1B1 (0.36) | CA2LMNATHRBCYP2C9GSR | |
| SCHEMBL12035115 | 0.76 | — | — | |
| SCHEMBL1985004 | 0.76 | — | — | |
| SCHEMBL450125 | 0.76 | — | — | |
| Bicarbonate SCHEMBL18124343 | 0.75 | CA1 (0.42) | CA2CA1CA9LMNACYP2D6 | |
| SCHEMBL3057990 | 0.74 | CYP2C19 (0.43) | LMNACYP2D6BLMCYP2C19MEN1 | |
| SCHEMBL3489123 | 0.74 | CYP2C19 (0.43) | LMNACYP2D6BLMCYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0957903-A4 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS INC (US) | 2002-10-09 | — | — | EP | claimed |
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2002-10-03 | — | — | US | claimed |
| WO-2002051395-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES | CODON PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| EP-0957903-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | Codon Pharmaceuticals, Inc. (US) | 1999-11-24 | — | — | EP | claimed |
| US-5990177-A | CYCLIC AND ACYCLIC MONO-, DI- AND TRIALCOHOLS AS STIMULANTS TO TREAT DISEASES MEDIATED BY DEFICIENCIES IN THE NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE/PROTEIN KINASE G SIGNAL TRANSDUCTION PATHWAY; CARDIOVASCULAR; SKIN; NERVOUS SYSTEM | CODON PHARMACEUTICALS, INC. (US) | 1999-11-23 | — | — | US | claimed |
| WO-1998055085-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-12-10 | — | — | WO | claimed |
| WO-1998011882-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-03-26 | — | — | WO | claimed |
| US-7250157-B2 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060120976-A1 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS (US) | 2006-06-08 | — | — | US | disclosed |
| US-6955804-B2 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DEMATICS (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040067209-A1 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS | 2004-04-08 | — | — | US | disclosed |
| US-6623724-B2 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2003-09-23 | — | — | US | disclosed |
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2002-10-03 | — | — | US | disclosed |
| US-6294585-B1 | ADMINISTERING NORBORNANE DIOL/TRIOL OR NORBORNENE DIOL/TRIOL DERIVATIVES FOR INCREASING DIFFERENTIATION OF MAMMALIAN NEURONAL CELLS | APPLIED GENETICS INCORPORATED DERMATICS | 2001-09-25 | — | — | US | disclosed |
| US-5990177-A | CYCLIC AND ACYCLIC MONO-, DI- AND TRIALCOHOLS AS STIMULANTS TO TREAT DISEASES MEDIATED BY DEFICIENCIES IN THE NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE/PROTEIN KINASE G SIGNAL TRANSDUCTION PATHWAY; CARDIOVASCULAR; SKIN; NERVOUS SYSTEM | CODON PHARMACEUTICALS, INC. (US) | 1999-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | TYR, MITF, MC1R | CA2 4062/4885CA1 4784/4885CA9 3927/4885 |
| US-20060120976-A1 | Dermatological compositions and methods | TYR, MITF, ALPG | CA2 3231/4885CA1 4173/4885CA9 2758/4885 |
| US-20040067209-A1 | Dermatological compositions and methods | TYR, MITF, ALPG | CA2 3231/4885CA1 4173/4885CA9 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.